Stock Fundamentals

Company Information

Company Name
Biomea Fusion Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US09077A1060
CIK: 0001840439
CUSIP: 09077A106
Currency: USD
Full Time Employees: 41
Phone: 650 980 9099
Fiscal Year End: December
IPO Date: Apr 16, 2021
Description:

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Address:

1599 Industrial Road, San Carlos, CA, United States, 94070

Directors & Officers

Name Title Year Born
Dr. Michael J. M. Hitchcock Ph.D. Interim CEO & Director 1950
Mr. Ramses M. Erdtmann Co-Founder, President, COO & Director 1963
Mr. Heow Tan Chief Technical & Quality Officer 1959
Caroline Perez- Dupont J.D. Senior Vice President of Legal NA
Dr. Thorsten Kirschberg Ph.D. Executive Vice President of Research 1970
Dr. Stephan Morris M.D. Chief Development Officer NA
Mr. Ravi Upasani Ph.D. Executive Vice President of Intellectual Property NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 11, 2025 Rainer M Erdtmann N/A Purchase 30.00K $1.43 $42.90K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 8.81M Mar 31, 2026 12.19% $0.00 0.00%
Vanguard Group Inc 2.97M Dec 31, 2025 4.11% $0.00 36.77%
Vanguard Capital Management, LLC 2.60M Mar 31, 2026 3.59% $0.00 0.00%
Aisling Capital Management LP 2.05M Mar 31, 2026 2.83% $0.66 0.00%
Renaissance Technologies Corp 1.31M Mar 31, 2026 1.82% $0.00 174.29%
Marshall Wace Asset Management Ltd 1.20M Mar 31, 2026 1.66% $0.00 3.29%
Citadel Advisors Llc 656.82K Mar 31, 2026 0.91% $0.00 0.00%
Mariner Wealth Advisors LLC 654.58K Mar 31, 2026 0.91% $0.00 11.77%
BlackRock Inc 641.44K Mar 31, 2026 0.89% $0.00 1.48%
Susquehanna International Group, LLP 629.87K Mar 31, 2026 0.87% $0.00 31.76%
Fideuram - Intesa Sanpaolo Private Banking Spa 557.04K Mar 31, 2026 0.77% $0.03 -11.79%
Geode Capital Management, LLC 548.19K Mar 31, 2026 0.76% $0.00 -2.61%
XTX Topco Ltd 530.54K Mar 31, 2026 0.73% $0.01 103.22%
UBS Group AG 515.56K Mar 31, 2026 0.71% $0.00 35.86%
Two Sigma Investments LLC 388.70K Mar 31, 2026 0.54% $0.00 -8.21%
Morgan Stanley - Brokerage Accounts 346.74K Mar 31, 2026 0.48% $0.00 -6.95%
Vanguard Fiduciary Trust Co 336.12K Mar 31, 2026 0.46% $0.00 0.00%
Jacobs Levy Equity Management, Inc. 310.51K Mar 31, 2026 0.43% $0.00 0.00%
Jane Street Group LLC 275.66K Mar 31, 2026 0.38% $0.00 296.75%
SUPERSTRING CAPITAL MANAGEMENT LP 250.00K Mar 31, 2026 0.35% $0.27 0.00%

Shares Statistics

Shares Outstanding: 72.30M
Shares Float: 67.44M
% Insiders: 716.60%
% Institutions: 3,889.50%
Short % Float: 24.43%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Compy Commingled Pl S 3.93M 5.44% ▲ 0.07% Apr 30, 2026
2 Fidelity Growth Company Fund 2.71M 3.75% ▲ 0.00% Apr 30, 2026
3 Vanguard Total Stock Mkt Idx Inv 1.89M 2.61% ▲ 0.00% Apr 30, 2026
4 Fidelity Growth Company K6 910.11K 1.26% ▼ 0.32% Apr 30, 2026
5 Fidelity Series Growth Company 804.70K 1.11% ▲ 0.00% Apr 30, 2026
6 Vanguard Institutional Extnd Mkt Idx Tr 636.37K 0.88% ▲ 0.00% Apr 30, 2026
7 Fidelity Select Biotechnology 452.66K 0.63% ▲ 0.00% Apr 30, 2026
8 Fidelity Extended Market Index 226.45K 0.31% ▲ 22.84% Apr 30, 2026
9 iShares Micro-Cap ETF 160.64K 0.22% ▲ 0.00% May 29, 2026
10 Extended Equity Market Fund B 149.40K 0.21% ▲ 0.00% Dec 31, 2025

Valuation Metrics

Enterprise Value: $41.14M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $84.59M
EBITDA: $-63.38M
Book Value: $0.26
Earnings/Share: $-0.55
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -79.32%
ROE (TTM): -189.44%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 5.23x 0.05x 0.50x N/A -0.02x
2024-12-31 3.15x 0.04x 0.35x N/A -0.02x
2023-12-31 7.84x 0.01x 0.15x N/A -0.02x
2022-12-31 6.17x 0.01x 0.16x -46.31x -0.01x
2021-12-31 38.08x 0.00x 0.04x -416.67x -0.01x
2020-12-31 38.43x 0.05x 0.92x N/A -0.05x
2019-12-31 0.93x 0.00x 1.08x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BMEA.US!